Zoetis Inc. (NYSE:ZTS) is Lansing Management LP’s 7th Largest Position

Lansing Management LP cut its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 73.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 20,131 shares of the company’s stock after selling 55,777 shares during the period. Zoetis accounts for 2.9% of Lansing Management LP’s holdings, making the stock its 7th biggest holding. Lansing Management LP’s holdings in Zoetis were worth $3,280,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of ZTS. Callahan Advisors LLC boosted its holdings in shares of Zoetis by 90.4% in the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock valued at $2,135,000 after buying an additional 6,221 shares in the last quarter. CIBC Asset Management Inc lifted its position in Zoetis by 24.1% during the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock valued at $38,617,000 after acquiring an additional 46,050 shares during the last quarter. Pensionfund Sabic boosted its stake in Zoetis by 55.6% in the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after acquiring an additional 4,000 shares in the last quarter. Schroder Investment Management Group grew its holdings in Zoetis by 2.6% in the fourth quarter. Schroder Investment Management Group now owns 245,726 shares of the company’s stock worth $40,036,000 after purchasing an additional 6,169 shares during the last quarter. Finally, PFW Advisors LLC acquired a new position in shares of Zoetis during the fourth quarter worth $1,764,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $153.58 on Friday. The company has a 50 day simple moving average of $158.91 and a two-hundred day simple moving average of $168.47. The stock has a market cap of $68.52 billion, a price-to-earnings ratio of 28.08, a PEG ratio of 2.78 and a beta of 0.92. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. As a group, analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.30%. Zoetis’s payout ratio is 36.56%.

Insider Buying and Selling

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares in the company, valued at $2,682,770. The trade was a 2.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,862 shares of company stock valued at $312,254 over the last ninety days. Company insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on ZTS shares. Piper Sandler raised their price objective on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Barclays upped their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Morgan Stanley lowered their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Finally, Stifel Nicolaus dropped their target price on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a research report on Monday, April 14th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Zoetis currently has an average rating of “Buy” and an average price target of $214.40.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.